raltegravir potassium · Msd Sub Merck · NDA 022145, 203045, 205786
Isentress
Earliest generic entry, as listed · earliest of 4 marketed strengths
11 Sep 2029
Other strengths are listed to 2 Jun 2030.
Blocked by patent: US 7754731.
Listed patents · 4 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 8771733 | substance, product, use U-257 | 2 Jun 2030 |
| US 7754731 | — | 11 Sep 2029 |
| US 7754731 | substance, product, use U-257 | 11 Mar 2029 |
| US 8852632 | substance, product, use U-257 | 28 Jan 2028 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 4
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 022145 · 001 · RLD | tablet, oral | EQ 400MG BASE | 2 Jun 2030 |
| 203045 · 001 · RLD | tablet, chewable, oral | EQ 25MG BASE | 11 Sep 2029 |
| 203045 · 002 · RLD | tablet, chewable, oral | EQ 100MG BASE | 2 Jun 2030 |
| 205786 · 001 · RLD | powder, oral | EQ 100MG BASE/PACKET | 11 Sep 2029 |